Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma;Subependimal dev hücreli astrositomlarda belirgin olmayan farklılaşma ve mTOR yolaǧı bozuklukları

Turk Patoloji Dergisi/Turkish Journal of Pathology

Volumn 28, Issue 2, 2012, Pages 95-103

  Barrows, Brad D ^a   Rutkowski, Martin J ^a   Gültekin, Şakir Humayun ^b   Parsa, Andrew T ^a   Tihan, Tarik ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Hamartin; Idh1; Idh2; Mtor complex; Olig2; Subependymal giant cell astrocytoma; Tuberin

Indexed keywords

CD34 ANTIBODY; HAMARTIN; INITIATION FACTOR 4E BINDING PROTEIN 1; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; KI 67 ANTIGEN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN S6; SYNAPTOPHYSIN; TUBERIN; TUMOR MARKER;

ADULT; AMBIGUUS NUCLEUS; ARTICLE; BRAIN DYSFUNCTION; CENTRAL NERVOUS SYSTEM; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; FEMALE; GENE MUTATION; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NERVE CELL DIFFERENTIATION; NEUROEPITHELIUM; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION; STAINING; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 84862649954     PISSN: 10185615     EISSN: 13095730     Source Type: Journal    
DOI: 10.5146/tjpath.2012.01107     Document Type: Article

References (29)

1. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ: Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004, 63:1236-1242
2. Povey S, Burley MW, Attwood J, Benham F, Hunt D, Jeremiah SJ, Franklin D, Gillett G, Malas S, Robson EB: Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann Hum Genet 1994, 58:107-127
3. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996, 59:400-406
4. Jansen FE, Notenboom RG, Nellist M, Goedbloed MA, Halley DJ, de Graan PN, van Nieuwenhuizen O: Differential localization of hamartin and tuberin and increased S6 phosphorylation in a tuber. Neurology 2004, 63:1293-1295
5. Tabuchi S, Takigawa H, Oka A, Mizuguchi M, Horie Y, Watanabe T: Subependymal giant cell astrocytoma with positive tuberin expression-case report. Neurol Med Chir 2003, 43:616-618
6. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, Mokbel K, Mansel RE: Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005, 41:1628-1636
7. Jozwiak J, Jozwiak S, Wlodarski P: Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 2008, 9:73-79
8. Rosner M, Fuchs C, Siegel N, Valli A, Hengstschlager M: New insights into the role of the tuberous sclerosis genes in leukemia. Leuk Res 2009, 33:883-885
9. Lee DF, Hung MC: All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 2007, 6: 3011-3014
10. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M: The mTOR pathway and its role in human genetic diseases. Mutat Res 2008, 659:284-292
11. Beretta L, Svitkin YV, Sonenberg N: Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection. J Virol 1996, 70:8993-8996
12. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002, 16:1472-1487
13. Bonnin JM, Rubinstein LJ, Papasozomenos SC, Marangos PJ: Subependymal giant cell astrocytoma. Significance and possible cytogenetic implications of an immunohistochemical study. Acta Neuropathol 1984, 62:185-193
14. Velasco ME, Dahl D, Roessmann U, Gambetti P: Immunohistochemical localization of glial fibrillary acidic protein in human glial neoplasms. Cancer 1980, 45:484-494
15. Ess KC, Kamp CA, Tu BP, Gutmann DH: Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology 2005, 64:1446-1449
16. Buccoliero AM, Franchi A, Castiglione F, Gheri CF, Mussa F, Giordano F, Genitori L, Taddei GL: Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology 2009, 29:25-30
17. Sharma MC, Ralte AM, Gaekwad S, Santosh V, Shankar SK, Sarkar C: Subependymal giant cell astrocytoma--a clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res 2004, 10:219-224
18. Han S, Santos TM, Puga A, Roy J, Thiele EA, McCollin M, Stemmer-Rachamimov A, Ramesh V: Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 2004, 64:812-816
19. Jozwiak J, Grajkowska W, Kotulska K, Jozwiak S, Zalewski W Zajaczkowska A, Roszkowski M, Slupianek A, Wlodarski P: Brain tumor formation in tuberous sclerosis depends on Erk activation. Neuromolecular Med 2007, 9:117-127
20. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59:490-498
21. Koenig MK, Butler IJ, Northrup H: Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008, 23:1238-1239
22. Krymskaya VP, Goncharova EA: PI3K/mTOR C1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009, 8:403-413
23. Otero JJ, Rowitch D, Vandenberg S: OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J Neurooncol 2010, 104:423-438
24. You H, Kim YI, Im SY, Suh-Kim H, Paek SH, Park SH, Kim DG, Jung HW: Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma. J Neurooncol 2005, 74:1-8
25. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008, 116:597-602
26. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174:1149-1153
27. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H: Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 2009, 117:653-656
28. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. New Eng J Med 2009, 360:765-773
29. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H: Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010, 177:2708-2714